Carbocysteines in the current therapy of lung diseases in children
https://doi.org/10.21508/1027-4065-2016-61-5-19-22
Abstract
The paper gives information on current mucoactive therapy with carbocysteine for acute and chronic bronchopulmonary diseases. The author’s observations during a multicenter study and the data available in the literature provide evidence that carbocysteine lysine salt (Fluifort) shows high clinical and immunological efficacies as a mucoregulatory and mucolytic agent used in children aged 2 to 17 years with acute and chronic bronchopulmonary diseases. The highest efficacy of carbocysteine lysine salt has been found in schoolchildren, which is attributable to the age-related features of the formation of the bronchial secretory apparatus and local immune system, as well as in the children with protracted and chronic inflammatory processes, including those associated with smoking.
About the Author
Yu. L. Mizernitsky
Academician Yu.E. Veltishchev Research Clinical Institute of Pediatrics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
References
1. Мизерницкий Ю.Л., Мельникова И.М. Муколитическая и отхаркивающая фармакотерапия при заболеваниях легких у детей. М: ИД «МЕДПРАКТИКА-М» 2013; 120. (Mizernitsky Yu.L., Mel’nikova I.M. Mucolytic and expectorant pharmacotherapy at diseases of lungs in children. Moscow: ID «MEDPRAKTIKA-M», 2013; 120. (in Russ))
2. Мизерницкий Ю.Л. Отхаркивающие и муколитические средства в терапии бронхолегочных заболеваний у детей. Руководство по фармакотерапии в педиатрии и детской хирургии (под общ. ред. А.Д. Царегородцева, В.А. Таболина). Т.1. Фармакотерапия в педиатрической пульмонологии (под ред. С.Ю. Каганова). М: МЕДПРАКТИКА-М 2002; 123–140. (Mizernitsky Yu.L. Expectorant and mucolytic tools in therapy of bronchopulmonary diseases at children. A.D. Caregorodcev, V.A. Tabolin (eds). Vol. 1. S.Yu. Kaganov (ed.). Moscow: MEDPRAKTIKA-M, 2002; 123–140. (in Russ))
3. Yoshida M., Nakayama K., Yasuda H. et al. Carbocisteine inhibits oxidant-induced apoptosis in cultured human airway epithelial cells. Respirology 2009; 14: 7: 1027–1034.
4. Zhang H., Zhang C.L. Effects of high-dose N-acetylcysteine on the lung tissues of rats exposed to silica. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2011; 29: 7: 510–513.
5. Новиков Ю.К. Мукоцилиарный транспорт как основной механизм защиты легких. РМЖ 2007; 15: 5: 357–360. (Novikov Yu.K. Mucociliary transport as main mechanism of protection of lungs. RMZh 2007; 15: 5: 357–360. (in Russ))
6. Ishiura Y., Fujimura M., Yamamori C. et al. Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients. Br J Clin Pharmacol 2003; 55: 6: 504–510.
7. Jartti T. Serial viral infections in infants with recurrent respiratory illnesses. Eur Respir J 2008; 32: 314–320.
8. Houtmeyers E., Gosselink R., Gayan-Ramirez G., Decramer M. Effects of drugs on mu-cus clearance. Eur Respir J 1999; 14: 2: 452–467.
9. Suer E., Sayrac S., Sarinay E. et al. Variation in the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine. J Infect Chemother 2008; 14: 4: 333–336.
10. Ndour C., Ahmed K., Nakagawa T. et al. Modulating effects of mucoregulating drugs on the attachment of Haemophilus influenza. Microb Pathol 2001; 30: 3: 121–127. 11. Yasuda H., Yamaya M., Sasaki T. et al. Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur Respir J 2006; 28: 1: 51–58.
11. Богданова А.В. Эффективность препарата Флуифорт в лечении рецидивирующего и хронического бронхитов у детей. Пульмонология детского возраста: проблемы и решения. Вып. 5. М., 2005; 77–79. (Bogdanova A.V. Effectiveness of a preparation Fluifort in treatment of recurrent and chronic bronchitis at children. Pul’monologija detskogo vozrasta: problemy i reshenija. Issue 5. Moscow, 2005; 77–79. (in Russ))
12. Мизерницкий Ю.Л., Ермакова И.Н. Современные мукоактивные препараты в терапии острых респираторных заболеваний у детей. Consilium medicum Педиатрия 2007; 1: 53–56. (Mizernitsky Yu.L., Ermakova I.N. The modern mucoactive drugs in therapy of acute respiratory diseases at children. Consilium medicum Pediatrija 2007; 1: 53–56. (in Russ))
13. Majima Y., Kurono Y., Hirakawa K. et al. Efficacy of combined treatment with S-carboxymethylcysteine (carbocysteine) and clarithromycin in chronic rhinosinusitis patients without nasal polyp or with small nasal polyp. Auris Nasus Larynx 2012; 39: 1: 38–47.
14. Делягин В.М., Быстрова Н.Ю. Антибактериальные и мукоактивные препараты. М.: Алтус, 1999; 70. (Deljagin V.M., Bystrova N.Yu. Antibacterial and mucoactive drugs. Moscow: Altus,1999; 70. (in Russ))
15. Maccio A., Madeddu C., Panzone F., Mantovani G. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother 2009; 10: 4: 693–703.
16. Чучалин А.Г., Абросимов В.Н. Кашель. Изд. 2-е, перераб. и доп. М.: Человек и лекарство, 2012; 127. (Chuchalin A.G., Abrosimov V.N. Cough. M.: Chelovek i lekarstvo, 2012; 127. (in Russ))
17. Braga P.C., Allegra L., Rampoldi C. et al. Long-lasting effects on rheology and clear-ance of bronchial mucus after shortterm administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration 1990; 57: 6: 353–358.
18. Braga P.C., Scaglione F., Scarpazza G. et al. Comparison between penetration of amoxi-cillin combined with carbocysteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue. Int J Clin Pharmacol Res 1985; 5: 5: 331–340.
19. Мизерницкий Ю.Л., Мельникова И.М., Батожаргалова Б.Ц. и др. Клиническая эффективность лизиновой соли карбоцистеина при острых и хронических бронхолегочных заболеваниях у детей. Вопр практ педиатрии 2011; 6: 5: 69–74. (Mizernitsky Yu.L., Mel’nikova I.M., Batozhargalova B.C. et al. Clinical effectiveness of lysine salt of a carbocysteine at acute and chronic bronchopulmonary diseases in children. Vopr prakt pediatrii 2011; 6: 5: 69–74. (in Russ))
20. Мизерницкий Ю.Л., Мельникова И.М., Батожаргалова Б.Ц. и др. Муколитическая терапия при заболеваниях нижних дыхательных путей. Врач 2009; 12: 78–82. (Mizernitsky Yu.L., Mel’nikova I.M., Batozhargalova B.C. et al. Mucolytic therapy in diseases of the lower respiratory tracts. Vrach 2009; 12: 78–82. (in Russ))
21. Батожаргалова Б.Ц., Мизерницкий Ю.Л. Проблема табакокурения у подростков и обоснование роли антисмокинговых программ в профилактике респираторной патологии и реабилитации хронических заболеваний легких. Детская и подростковая реабилитация 2011; 2: 17: 52–60. (Batozhargalova B.C., Mizernitsky Yu.L. Smoking problem at teenagers and justification of a role the antismoking programs in prophylaxis of respiratory pathology and rehabilitation of chronic lungs diseases. Detskaja i podrostkovaja reabilitacija 2011; 2: 17: 52–60. (in Russ))
Review
For citations:
Mizernitsky Yu.L. Carbocysteines in the current therapy of lung diseases in children. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2016;61(5):19-22. (In Russ.) https://doi.org/10.21508/1027-4065-2016-61-5-19-22
Views:
896
Email this article 